Lesson plan
Esm1
Endothelial cell-specific molecule 1 is a protein that in humans is encoded by the ESM1 gene. This gene encodes a secreted protein which is mainly expressed in the endothelial cells in human lung and kidney tissues. The expression of this gene is regulated by cytokines, suggesting that it may play a role in endothelium-dependent pathological disorders. The transcript contains multiple polyadenylation and mRNA instability signals. The ESM-1 gene product is also called endocan since 2001, when it was characterized as a dermatan sulfate proteoglycan by Bechard et al. Recently, endocan / ESM-1 has been described as a specific biomarker of tip cells during neoangiogenesis by independent teams. Endocan expression has been shown to be increase in presence of pro-angiogenic growth factors such as vascular endothelial growth factor (VEGF) or fibroblast growth factor 2 (FGF-2). In hypervascularized cancers, overexpression of endocan has been detected by immunohistochemistry using monoclonal antibodies against endocan / ESM-1.
Article summary
Endothelial cell-specific molecule 1 is a protein that in humans is encoded by the ESM1 gene. This gene encodes a secreted protein which is mainly expressed in the endothelial cells in human lung and kidney tissues. The expression of this gene is regulated by cytokines, suggesting that it may play a role in endothelium-dependent pathological disorders. The transcript contains multiple polyadenylation and mRNA instability signals. The ESM-1 gene product is also called endocan since 2001, when it was characterized as a dermatan sulfate proteoglycan by Bechard et al. Recently, endocan / ESM-1 has been described as a specific biomarker of tip cells during neoangiogenesis by independent teams. Endocan expression has been shown to be increase in presence of pro-angiogenic growth factors such as vascular endothelial growth factor (VEGF) or fibroblast growth factor 2 (FGF-2). In hypervascularized cancers, overexpression of endocan has been detected by immunohistochemistry using monoclonal antibodies against endocan / ESM-1.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.